These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20838908)

  • 1. PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative.
    Kudo T; Ueda M; Konishi H; Kawashima H; Kuge Y; Mukai T; Miyano A; Tanaka S; Kizaka-Kondoh S; Hiraoka M; Saji H
    Mol Imaging Biol; 2011 Oct; 13(5):1003-10. PubMed ID: 20838908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1alpha.
    Ueda M; Kudo T; Kuge Y; Mukai T; Tanaka S; Konishi H; Miyano A; Ono M; Kizaka-Kondoh S; Hiraoka M; Saji H
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1566-74. PubMed ID: 20428865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.
    Kudo T; Ueda M; Kuge Y; Mukai T; Tanaka S; Masutani M; Kiyono Y; Kizaka-Kondoh S; Hiraoka M; Saji H
    J Nucl Med; 2009 Jun; 50(6):942-9. PubMed ID: 19443598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an oxygen-sensitive degradable peptide probe for the imaging of hypoxia-inducible factor-1-active regions in tumors.
    Ueda M; Ogawa K; Miyano A; Ono M; Kizaka-Kondoh S; Saji H
    Mol Imaging Biol; 2013 Dec; 15(6):713-21. PubMed ID: 23689986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry.
    Ueda M; Kudo T; Mutou Y; Umeda IO; Miyano A; Ogawa K; Ono M; Fujii H; Kizaka-Kondoh S; Hiraoka M; Saji H
    Cancer Sci; 2011 Nov; 102(11):2090-6. PubMed ID: 21824221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.
    Ruivo E; Adhikari K; Elvas F; Fissers J; Vangestel C; Staelens S; Stroobants S; Van der Veken P; Wyffels L; Augustyns K
    Nucl Med Biol; 2019; 76-77():36-42. PubMed ID: 31707309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of a method of high-contrasted nuclear medical imaging of hypoxia-inducible factor-1-active tumor by using a pretargeting approach].
    Ueda M
    Yakugaku Zasshi; 2012; 132(5):595-600. PubMed ID: 22687695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
    Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
    J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
    Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy.
    Viola RJ; Provenzale JM; Li F; Li CY; Yuan H; Tashjian J; Dewhirst MW
    AJR Am J Roentgenol; 2008 Dec; 191(6):1779-84. PubMed ID: 19020250
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
    Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA; Meares CF; Osen M
    J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled probes targeting hypoxia-inducible factor-1-active tumor microenvironments.
    Ueda M; Saji H
    ScientificWorldJournal; 2014; 2014():165461. PubMed ID: 25215311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bifunctional phage-based pretargeted imaging of human prostate carcinoma.
    Newton-Northup JR; Figueroa SD; Quinn TP; Deutscher SL
    Nucl Med Biol; 2009 Oct; 36(7):789-800. PubMed ID: 19720291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake?
    Mees G; Dierckx R; Vangestel C; Laukens D; Van Damme N; Van de Wiele C
    Mol Imaging; 2013; 12(1):49-58. PubMed ID: 23348791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Bioevaluation of Novel [
    Yang X; Wang F; Zhu H; Yang Z; Chu T
    Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species Generation.
    Fuchs K; Kuehn A; Mahling M; Guenthoer P; Hector A; Schwenck J; Hartl D; Laufer S; Kohlhofer U; Quintanilla-Martinez L; Reischl G; Röcken M; Pichler BJ; Kneilling M
    J Nucl Med; 2017 May; 58(5):853-860. PubMed ID: 28183987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice.
    Serganova I; Doubrovin M; Vider J; Ponomarev V; Soghomonyan S; Beresten T; Ageyeva L; Serganov A; Cai S; Balatoni J; Blasberg R; Gelovani J
    Cancer Res; 2004 Sep; 64(17):6101-8. PubMed ID: 15342393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.